VYGR (15) BDTX (59) ENGN (34) OTLK (38) ⌘ Pro Terminal →

LENZ Therapeutics Inc. (LENZ) — RQD Stock Rating Cockpit

$3.05 -12.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.97

LENZ Therapeutics Inc. (LENZ) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $109.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LENZ Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LENZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, LENZ Therapeutics Inc. (NASDAQ: LENZ) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.05 (-12.61% 1D, market cap $109.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LENZ ranks #443 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LENZ compare to VYGR and BDTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LENZ carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.8%. By comparison, VYGR (Voyager Therapeutics Inc.) holds a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M) and BDTX (Black Diamond Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M). Among the 5-stock peer group, LENZ leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LENZ?

▼

Per LENZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001815776), LENZ Therapeutics Inc. generated $19.1M in revenue, -$82.1M in net income, and -$70.0M in free cash flow against $305.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.97 (-2.46%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LENZ)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY LENZ SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (30% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$3.64-10.2% Next Q

Q2 (-2Q)

Grade D$3.27-3.4% Next Q

Q3 (-1Q)

Grade D$3.16-3.5% Next Q

Current

Grade D$3.05-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LENZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LENZ currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.07) and Max Pain ($3.20) forces dealer call-delta covering toward $33.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LENZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LENZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

35.830 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.19>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $3$3.05H: $32

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LENZ

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-27.8% ROIC with 96.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (35)

Altman-Z 2.19 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

17/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like LENZ

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LENZ)

✓Walkthrough of LENZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LENZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -66.04%▼ DESCENDING CHANNEL

2026-10-30O $3.38H $3.42L $3.04C $3.05VOL 2.26M

RES: $3.77SUP: $0.97SMA50: $4.07SMA200: $8.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LENZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LENZ Butterfly Map → + Track LENZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LENZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LENZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LENZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LENZ)

Health Care Rank #443 of 1016 ⚔️ VYGR vs LENZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LENZ vs. VYGR, BDTX, ENGN, OTLK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LENZ Therapeutics Inc. (LENZ) ranks #443 by composite RQD confidence (44/100, grade D) and #647 by equity capitalization ($109.7M). Within this direct 5-issuer industry benchmark cohort, LENZ leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with LENZ at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LENZ ACTIVE LENZ Therapeutics Inc.	D	44/100	—	96.0%	-27.8%	-12.61%	$109.7M	Benchmark Subject
VYGR Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	-2.27%	$108.4M	/vygr-vs-lenz →
BDTX Black Diamond Therapeutics Inc.	C-	59/100	—	—	10.8%	-4.30%	$106.9M	/bdtx-vs-lenz →
ENGN enGene Therapeutics Inc.	E	34/100	—	—	-35.0%	0.00%	$102.5M	/engn-vs-lenz →
OTLK Outlook Therapeutics Inc.	D-	38/100	—	4.0%	-35.0%	-5.15%	$120.1M	/otlk-vs-lenz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001815776

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LENZ Therapeutics Inc. (LENZ) reported GAAP revenue of $19.1M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$82.1M, operating cash flow of -$69.2M, and free cash flow of -$70.0M (-16.9% YoY). On the balance sheet, LENZ closed FY2025 with $305.9M in total assets against $0 in total debt (Altman Z-Score: 2.19, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$19.1M	-$82.1M	-$69.2M	-$70.0M	$305.9M	—
FY2024 (FY)	2024-12-31	$0	-$49.8M	-$59.4M	-$59.9M	$215.3M	—
FY2023 (FY)	2023-12-31	$0	-$70.0M	-$60.4M	-$60.4M	—	—

3. LENZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LENZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LENZ compare to VYGR and BDTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LENZ?

Where is LENZ trading relative to its 50-day, 200-day, and 52-week technical levels?

LENZ last traded at $3.05 (-12.61% on volume of 2,264,278 shares), positioning the stock -25.06% below its 50-day simple moving average ($4.07) and -61.97% below its 200-day simple moving average ($8.02). Across its 52-week range of $3.00 to $32.13, LENZ sits at the 0.2% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.67 to $3.43).

LENZ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LENZ stock right now?

LENZ Therapeutics Inc. (LENZ) currently earns a Roarable Rating of D (Sell — SELL) with 44/100 RQD Confidence. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

What is LENZ's 12-month price target and RQD AI Jury consensus?

LENZ's 12-month base price target is $2.86 (range $2.23 to $33.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LENZ RQD Cockpit LENZ 12M Forecast LENZ Earnings & Move LENZ Dividends & DRIP LENZ Insiders & 13F LENZ Whale Options LENZ Profit Sankey LENZ News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LENZ — LENZ Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LENZ scores 44 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The fundamental cash engine pillar scores 7 out of 20, reflecting ROIC of -27.8% and an FCF yield of 0%, which indicates the business is not currently generating returns on invested capital or free cash flow. The whale 13F flow pillar scores 14 out of 20 for institutional accumulation and options positioning, the strongest pillar in the set, though the source does not itemize the underlying holder activity. The insider conviction pillar scores 3 out of 20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest signal in the rating. The macro regime fit pillar scores 13 out of 20 with a beta of 1.0. The forensic balance sheet pillar scores 7 out of 20, consistent with an Altman Z-Score of 2.19, a Piotroski F-Score of 3 out of 9, and a debt-to-equity ratio of 0.5. For a prospective investor, the rating frames a stock where the valuation tradeoff is dominated by negative operating economics: the cash engine and insider signals are weak, and the upside case depends on institutional positioning and a balance sheet that the source describes as only partially sound.

Business

LENZ Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company has a market capitalization of $0.1B. The source data does not specify its products, customer base, or revenue model beyond reported revenue figures in the financials. Per the recent news wire, the company has announced a consumer marketing focused reorganization and a CEO succession, and analysts have referenced its VIZZ launch.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$19.1M	$-91.1M	$-82.1M	N/A	$-70.0M	$25.2M	N/A
FY 2024	$0.0M	$-58.6M	$-49.8M	N/A	$-59.9M	$20.2M	N/A
FY 2023	$0.0M	$-72.4M	$-70.0M	N/A	$-60.4M	N/A	N/A

Per the SEC financials and market data, operating margin is -60%, net margin is -60%, and gross margin is 96%. ROIC is -27.8%. Per the Roarable RQD rating, the Altman Z-Score is 2.19, the Piotroski F-Score is 3 out of 9, and debt-to-equity is 0.5. Reported FY 2025 revenue of $19.1M follows zero reported revenue in the two prior periods, and operating losses widened across the three periods.

Recent Catalysts & News Wire Analysis

Q3 2026 results and reorganization (MARKET WIRE, YELLOW): The company reported third quarter 2026 financial results alongside a strategic consumer marketing focused reorganization and CEO succession.
VIZZ launch expectations (RISK WATCH, RED): A Yahoo Finance report states analysts cut VIZZ launch expectations, with fair value falling accordingly.
Workforce reduction (RISK WATCH, RED): A Fierce Pharma report describes a 75% workforce cut and CEO shakeup alongside the Q3 update.
Price target cuts (RISK WATCH, RED): TradingView reports a 12-month price target cut to $22, implying 504% upside; Investing.com reports H.C. Wainwright cut its target to $16.
Cash burn (MARKET WIRE, YELLOW): A Yahoo Finance report links a stock rally to Q3 results that expose cash burn.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Analyst View & Smart Money Ownership

Per the analyst data and holders sections, no consensus rating, price target set, Form 4 insider trades, 13F whale holdings, or Congressional trades are provided in the structured fields. Press reports in the news wire reference individual price target actions (a cut to $22 and a cut to $16) but the source does not provide a consensus rating.

Open Questions

What are the company's specific products and revenue sources, and how much of FY 2025 revenue is tied to the VIZZ launch?
What is the size and timing of cash runway given $25.2M in cash against $-70.0M in FY 2025 free cash flow?
What are the terms and timing of the CEO succession and the 75% workforce reduction?
Which institutional holders drive the whale 13F flow pillar, and in which direction are their positions changing?
What drove the reported debt figure to remain unavailable, and what is the company's financing structure?

LENZ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LENZ Therapeutics Inc. (LENZ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LENZ Debate Forum (3) ↓

🟡 MARKET WIRE LENZ Therapeutics • 6h ago

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

LENZ Therapeutics report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 9h ago

LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations

Yahoo Finance report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Fierce Pharma • 12h ago

Lenz reports 75% workforce cut, CEO shakeup alongside Q3 earnings update

Fierce Pharma report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 15h ago

LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 504% Upside

TradingView report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com • 18h ago

Lenz Therapeutics stock price target cut to $16 by H.C. Wainwright

Investing.com report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

LENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Expose Cash Burn

Yahoo Finance report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

LENZ Therapeutics, Inc. Estimates – NASDAQ:LENZ

TradingView report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

LENZ Therapeutics reports 50% Q3 sales growth, CEO to step down

Investing.com report covering LENZ Therapeutics Inc. (LENZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LENZ Bull vs. Bear Conversation Board — What's Your Call at $3.05?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LENZ 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.68 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LENZ (D • RQD 44/100) a Buy at $3.05?

Welcome to the LENZ (LENZ Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.41 (-21.0%)

Spot @ $3.05

Pump the brakes on LENZ — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LENZ, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless LENZ Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.78 (+23.9%)

Spot @ $3.05

LENZ cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LENZ, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.05 (52-wk range $3.00 - $32.13), any beat on forward guidance forces shorts and underweight funds to chase.